

CURRICULUM VITAE

MICHAEL ROY McCLUNG, M.D.

WORK ADDRESS: Oregon Osteoporosis Center
5050 NE Hoyt, Suite 651
Portland OR 97213

STATUS:

DEGREES, DIPLOMAS AND LICENSES:

- | | |
|--------------|---|
| 1961-1965 | B.A., Rice University, Houston, TX |
| 1965-1969 | M.D., University of Texas Southwestern Medical School at Dallas, TX |
| 1972 | Certification, American Board of Internal Medicine |
| 1975 | Certification, Specialty Board of Endocrinology and Metabolism |
| 1969-1976 | Medical Licensure, State of Texas |
| 1976-present | Medical Licensure, State of Oregon |
| 1996 | Certification, International Society of Clinical Densitometry |

POSTGRADUATE TRAINING:

- 1969-1970 Medicine Internship, Parkland Memorial Hospital, Dallas, Texas.

1970-1972 Medicine Residency, Parkland Memorial Hospital, Dallas, Texas.

1972-1975 Staff and Clinical Associate, Clinical Endocrinology Branch, NIAMDD, National Institutes of Health, Bethesda, MD.

1975 Graduate, Medical Radioisotope Course, National Institutes of Health, Bethesda, MD

HOSPITAL APPOINTMENTS AND ACADEMIC POSITIONS:

- | | |
|-------------|---|
| 1976-1981 | Assistant Professor of Medicine, Division of Endocrinology, Oregon Health Sciences University, Portland, OR |
| 1977-1980 | Consultant in Endocrinology, Portland VA Medical Center, Portland, OR |
| 1977-1987 | Founding Director, Endocrinology Clinic, University Hospital, Portland, OR |
| CV-July2002 | |

1976-1980	Staff Physician, Portland VA Medical Center, Portland, OR
1980-1987	Chief, Section of Endocrinology, Portland VA Medical Center
1981-1987	Founding Director, Bone and Mineral Clinic, University Hospital, Portland, OR
1981-present	Associate Professor of Medicine, Division of Endocrinology, Oregon Health Sciences University, Portland, OR
1985-1987	Founding Director, Osteoporosis Center, University Hospital, Portland, OR
1987-present	Assistant Director, Department of Medical Education, Providence Portland Medical Center, Portland, OR
1987-present	Founding Director, Oregon Osteoporosis Center, Portland, OR

MEMBERSHIPS IN SCIENTIFIC ASSOCIATIONS:

American Association of Clinical Endocrinologists
 American College of Endocrinology, Fellow
 American Society for Bone and Mineral Research
 The Endocrine Society
 International Society for Clinical Densitometry
 Multnomah County Medical Society
 Oregon Medical Association
 The North American Menopause Society

RECENT HONORS AND AWARDS:

2002 NAMS/Eli Lilly and Company Award for innovations in Osteoporosis (2002)

CURRENT COMMITTEE AND SOCIETY APPOINTMENTS:

Member, Scientific-Educational Advisory Committee, National Osteoporosis Foundation (1995-present)
 Member, Medical Advisory Board, The Paget Foundation (1991-present)
 Member, Council of Scientific Advisors, International Osteoporosis Foundation, (1999-present)

EDITORIAL CONSULTANT AND BOARD MEMBERSHIPS:

Editorial Board, Osteoporosis Today (2001)
 Editorial Board, North American Menopause Society (2001-present)
 Associate Editor, Journal of Clinical Densitometry (2002)

Reviewer for Osteoporosis International, Journal of Bone and Mineral Research, Calcified Tissue International, Journal of the American Medical Association, New England Journal of Medicine, American Journal of Medicine, Journal of Clinical Endocrinology and Metabolism, Obstetrics & Gynecology, The Journal of Musculoskeletal Medicine, Women's Health in Primary Care, Arthritis and Rheumatism, Journal of Clinical Densitometry, Archives of Internal Medicine, Menopause Medicine

BIBLIOGRAPHY: CV-2002

PEER REVIEWED ARTICLES

1. Gershengorn MC, **McClung MR**, Chu EW, Hanson TAS, Weintraub BD, Robbins J. Fine-needle aspiration cytology in the pre-operative diagnosis of thyroid nodules. *Ann Intern Med* 1977; 87: 265-269.
2. **McClung M**, Miller, J. Evidence for a role of cyclic AMP-dependent protein kinase in TSH action. *Tr Assoc Am Physicians* 1977;90:270-280.
3. **McClung M**, Miller J. Reversible inhibition by diamide of cyclic AMP-dependent protein kinases from bovine thyroid. *Biochem Biophys Res Commun.* 1977;76:910-916.
4. Yasuda, N, **McClung MR**, Greer MA. Demonstration of "big" CRF (corticotropin-releasing factor) in bovine hypophyseal stalk. *Biochem Biophys Res Commun* 1978;81:1187-1194.
5. Yasuda N, **McClung M**, Greer MA. Evidence that hypothalamic hypophysiotropic hormones (CRF, TRF) exist as large proteins in vivo. *Tr Assoc Am Physicians* 1978;91:333-342.
6. Margolin D, Hammerstad J, Orwoll E, **McClung M**, Calhoun D. Intracranial calcifications in hyperparathyroidism associated with gait apraxia and parkinsonism. *Neurology* 1980;80:1005-1007.
7. Jordan RM, Kendall JW, **McClung MR**, Kammer H. Concentration of human chorionic gonadotropin in the cerebrospinal fluid of patients with germinal cell hypothalamic tumors. *Pediatrics* 1980;65:121-124.
8. Koler RD, **McClung MR**, Peterson LL, Jones MB. Physiologic and genetic alterations in human red cell DPGM. *Hemoglobin* 1980;4:593-600.
9. Illingworth D, **McClung MR**, Connor WE, Alaupovic P. Familial hypercholesterolemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolemia. *Clin Endocrinol* 1981;14:145-152.
10. Orwoll ES, Margolin DI, Hammerstad JP, Calhoun AD, **McClung MR**. Hyperparathyroidism and intracerebral calcification. *Mineral Electrolyte Metab* 1981;5:273-279.
11. McCarron DA, Rankin LI, Bennett WM, Krutzik S, **McClung MR**, Luft FC. Urinary calcium excretion at extremes of sodium intake in normal man. *Am J Nephrol* 1981;1:84-90.
12. Orwoll E, Silbert J, McClung M. Asymptomatic neonatal familial hypercalcemia. *Pediatrics* 1982;69:109-111.
13. Lowe DK, Orwoll ES, **McClung MR**, Cawthon AK, Peterson CG. The special problem of hyperparathyroidism and pregnancy. *Amer J Surg* 1983;145:611-614.
14. Orwoll E, Kopel A, Opsahl Z, Roberts L, Endres D, **McClung M**. Hypochlorite iodination of parathyroid peptides. *J Clin Lab Med* 1985;105:247-253.
15. Orwoll ES, **McClung MR**. Pseudofractures in patients with low-turnover osteoporosis. *West J Med* 1985; 143:239-242.
16. Ivie WM, Orwoll ES, **McClung MR**, Kenny TA, Swanson JR. Mid-molecule parathyroid hormone assay comparison. *Clinical Biochemistry* 1986;19:41-45.
17. Orwoll ES, Kane-Johnson N, Cook J, Roberts L, Strasik L, **McClung M**. Acute parathyroid hormone secretory dynamics: hormone secretion from normal primate and adenomatous human tissue in response to changes in extracellular calcium concentration. *J Clin Endocrinol Metab* 1986;62:950-955.
18. Klein KB, Orwoll ES, Lieberman DA, Meier DE, **McClung MR**, Parfitt AM. Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis. *Gastroenterology* 1987;92:608-616.
19. Hauty M, Swartz K, **McClung M**, Lowe DK. Technetium-thallium scintiscanning for localization of parathyroid adenomas and hyperplasia. *Amer J Surg* 1987;153:479-486.
20. Orwoll ES, Weigel RM, Oviatt SK, Meier DE, **McClung MR**. Serum protein concentrations and bone mineral content in aging normal men. *Am J Clin Nutr* 1987;46:614-621.
21. Orwoll ES, Weigel RM, Oviatt SK, **McClung MR**, Deftos LJ: Calcium and cholecalciferol: effects of small supplements in normal men. *Am J Clin Nutr.* 1988;48:127-130.

22. Orwoll ES, Oviatt S, **McClung M**. The histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis. *J Bone Miner Res* 1989;4:81-88.
23. Orwoll ES, Ferar J, Oviatt S, **McClung M**, Huntington K. The relationship of swimming exercise to bone mass in men and women. *Arch Int Med* 1989;149:2197.
24. Orwoll ES, Oviatt S, **McClung M**, Deftos LJ, Sexton G. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. *Ann Int Med* 1990;112:29-34.
25. Mazess R, Chesnut III CH, **McClung M**, Genant H. Enhanced precision with dual-energy x-ray absorptiometry. *Calcif Tissue Int* 1992;51:14-17.
26. Faulkner KG, **McClung MR**, Coleman LJ, Kingston-Sandahl E. Quantitative ultrasound of the heel; correlation with densitometric measurements at different skeletal sites. *Osteoporos Int* 1994;4:42-47.
27. Faulkner KG, **McClung MR**, Schmeer MS, Roberts LA, Gaither KW. Densitometry of the radius using single and dual energy absorptiometry. *Calcif Tissue Int* 1994;54:208-211.
28. Faulkner KG, **McClung MR**, Cummings SR. Automated evaluation of hip axis length for predicting hip fracture. *J. Bone Miner Res* 1994;9:1065-1070.
29. Brodowicz GR, Mansfield RA, **McClung MR**, Althoff SA. Measurement of body composition in the elderly: dual energy X-ray absorptiometry, underwater weighing, bioelectrical impedance analysis, and anthropometry. *Gerontology* 1994;40:332-339.
30. Faulkner KG, **McClung MR**. Quality control of DXA instruments in multi-center trials. *Osteoporos Int* 1995;5:218-227.
31. Faulkner KG, **McClung MR**. Bilateral comparison of femoral bone density and hip axis length from single and fan beam DXA scans. *Calcif Tissue Int* 1995;56:26-31.
32. Chesnut CH III, **McClung MR**, Ensrud KE, Bell NH, Genant, HK, Harris, Singer, FR, Stock, JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. *Am. J. Med.* 1995; 99:144-152.
33. **McClung MR**, Tou CKP, Goldstein N, Picot C. Tiludronate therapy for Paget's disease of bone. *Bone* 1995;17:493S-496S.
34. Miller PD, Bonnick SL, Rosen CJ, **McClung MR**. Consensus of an international panel on the clinical utility of bone mass measurements in the detection of low bone mass in the adult population. *Calcif Tissue Int* 1996;58:207-214.
35. Ravn P, Overgaard K, Huang C, Ross PD, Green D, **McClung M**. Comparison of bone densitometry of the phalanges, distal forearm and axial skeleton in early postmenopausal women participating in the EPIC Study. *Osteoporos Int.* 1996;6:308-313.
36. Miller PD, Bonnick SL, Rosen CL, Altman RD, Avioli LV, Dequeker J, Felsenberg, Genant HK, Gennari C, Harper, KD, Hodzman AB, Kleerekoper M, Mautalen CA, **McClung MR**, Meunier PJ, Nelson DA, Peel NFA, Raisz LG, Recker RR, Utian WH, Wasnich RD, Watts N. Clinical utility of bone mass measurements in adults: Consensus of an International Panel. *Seminars in Arthritis and Rheumatism* 1996;25:361-372.
37. Ettinger B, Miller, P, **McClung MR**. Use of bone densitometry results for decisions about therapy for osteoporosis. *Letter to Editor*. *Ann Int Med* 1996;125:623.
38. Ross PD, He Y-F, Yates AJ, Coupland C, Ravn P, **McClung M**, Thompson D, Wasnich RD. Body size accounts for most differences in bone density between Asian and Caucasian women. *Calcif Tissue Int* 1996;59:339-343.
39. Faulkner KG, Roberts LA, **McClung MR**. Discrepancies in normative data between Lunar and Hologic DXA Systems. *Osteoporos Int* 1996;6:432-436.
40. Miller PD, **McClung M**. Prediction of fracture risk I: bone density. *Am J. Med Sci* 1996;312:257-259.
41. Hla M, Davis J, Ross PD, Wasnich RD, Yates J, Christiansen C, Hosking D, **McClung MR**. A multi-center study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. *Am J Clin Nutrition* 1996;4:354-360.

42. Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AO, **McClung MR**, Kimmel DB, Gertz BJ, Hale E, Polvino WJ. Dose-response relationships for alendronate treatment in osteoporotic elderly women. *J Clin Endocrinol Metab* 1997;82:265-274.
43. Siris ES, Chines AA, Altman RD, Brown JP, Johnston C, Lang R, **McClung MR**, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. *J Bone Miner Res* 1998;13:1032-1038.
44. Stock, JL, Bell NH, Chesnut CH, Ensrud KE, Genant HK, Harris ST, **McClung MR**, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC. **McClung MR**, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. *Clin Ther* 1999;21:1025-1044.
45. **McClung M**, Clemmesen B, Daifotis A, Gilchrist N, Eisman J, Weinstein RS, Fuleihan G, Reda C, Yates AJ, Ravn P. The use of alendronate for prevention of postmenopausal osteoporosis. *Ann Intern Med* 1998;128:253-261.
46. Hosking D, Chilvers C, Christiansen C, Ravn P, Wasnich R, Ross P, **McClung M**, Balske A, Yates AJ, Thompson D, Daley M: Prevention of early postmenopausal bone loss with oral alendronate. *N Engl J Med* 1998;338:485-492.
47. Earnshaw SA, Keating N, Hosking DJ, Chilvers CE, Ravn P, **McClung M**, Wasnich RD. Tooth counts do not predict bone mineral density in early postmenopausal Caucasian women. EPIC study group. *Int J Epidemiol*. 1998;27:479-483.
48. Hosking DJ, Ross PD, Thompson DE, Wasnich RD, McClung M, Bjarnason NH, Ravn P, Cizza G, Daley M, Yates AJ Evidence that increased calcium intake does not prevent early postmenopausal bone loss. *Clin Ther*. 1998;20:933-944.
49. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ. Christiansen C. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. *J Bone Miner Res*. 1999;14:1622-1627.
50. Ravn, P, Hosking D, Thompson D, Cizza G, Wasnich, RD, **McClung M**, Yates, AJ, Bjarnason NH, Christiansen C. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. *J Clin Endocrinol Metab* 1999;84:2363-2368.
51. Meunier PJ, Delmas PD, Eastell R, **McClung MR**, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. *Clin Ther* 1999;21:1025-1044.
52. **McClung MR**. Therapy for fracture prevention (Editorial): *JAMA* 1999;282:687-689.
53. Grauer A, Bone H, McCloskey EV, **McClung M**, Gutteridge DH, Lyles KW, Mautalen C, Rodan G, Wallach S. Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. *J Bone Miner Res* 1999;14(Suppl 2):74-78.
54. Ravn P, Bidstrup M, Wasnich RD, Davis JW, **McClung MR**, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. *Ann Int Med* 1999;131:935-942.
55. Metz JA, Morris CD, Roberts LA, **McClung MR**, McCarron DA. Blood pressure and calcium intake are related to bone density in adult males. *Br J Nutr* 1999 May;81:383-388.
56. Cook DJ, Guyatt GH, Adachi JD, Epstein RS, Juniper EF, Austin PA, Clifton J, Rosen CJ, Kessenich CR, Stock JL, Overdorf J, Miller PD, Erickson AL, **McClung MR**, McClung BL, Griffith LE, Ioannidis G. Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. *Osteoporosis Quality of Life Study Group*. *Osteoporos Int* 1999;10:207-213.
57. Kleerekoper M, Deftos L, Khosla S, Marcus R, Matrici M, **McClung M**, Rosen C, Shane E: Osteology: further debate. Letter to Editor. *J Bone Miner Res* 1999;14:1017.
58. Schnitzer T, Bone HG, Crepaldi G, Adami S, **McClung M**, Kiel D, Felsenberg D, Recker RR, Toniro RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora II AC, Kasur A, Thompson

- DE, Yates J, Orloff JJ. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. *Aging Clin Exp Res* 2000;12:1-12.
59. Ravn P, Weiss SR, Rodriguez-Portales JA, **McClung MR**, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. *J Clin Endocrinol Metab* 2000;85:1492-1497.
 60. Hla MM, Davis JW, Ross PD, Yates J, Wasnich RD, Ravn P, **McClung M**, Hosking D. Relation between body composition and biochemical markers of bone turnover among early postmenopausal women. *J Clin Densitometry* 2000;3:365-371.
 61. **McClung MR**, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adamo S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Richard D, Wasnich, M.D., Maria Greenwald, M.D., Jean-Marc Kaufman, M.D., Ph.D. Charles H. Chesnut, III, M.D., Reginster J-Y. Effect of risedronate on the risk of hip fracture in elderly women. *N Engl J Med* 2001;344:333-340.
 62. Sarno M, Sarno L, Baylink D, Drinkwater B, Farley S, Kleerekoper M, Lang R, Lappe J, Licata A, **McClung M**, Miller P, Nattrass S, Recker R, Schwartz EN, Tucci JR, Wolf S, Powell H, Tjersland G, Warnick GR. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease. *Clin Chem Lab Med* 2001;39:223-228.
 63. Drake WM, **McClung M**, Njeh CF, Genant HK, Rosen C, Watts N, Kendler DL. Multisite bone ultrasound measurement on North American female reference population. *J Clin Densitometry*; 2001:239-248.
 64. Gallagher JC, Baylink DJ, Freeman R, **McClung M**. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. *J Clin Endocrinol Metab* 2001;86:4717-4726.
 65. Gallagher JC, Ettinger B, Gass MLS, Kagan R, McClung BL, **McClung MR**, Simon JA. Management of postmenopausal osteoporosis: Position statement of the North American Menopause Society. *Menopause* 2002;9:84-101.
 66. El-Hajj Fuleihan G, Stock JL, **McClung MR**, Saifi G. A national random survey of bone mineral density reporting in the United States. *J Clin Densitometry* 2002;5:3-9.
 67. Greenspan SL, Schneider DL, **McClung MR**, Miller PD, Schnitzer TJ, Bonin R, Smith ME, DeLucca P, Gormley GJ, Melton ME. Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. *Ann Int Med* 2002;136:742-746.
 68. Brown JP, Kendler DL, **McClung MR**, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. *Calcif Tissue Int* 2002;71(2):103-111.

INVITED PAPERS

1. **McClung MR**, Greer MA. Treatment of hyperthyroidism. *Ann Rev Med* 1980;31:383-404.
2. **McClung M**. Improved bone density testing with dual energy x-ray absorptiometry. *Contemporary OB/GYN* 1989;34:9-23.
3. **McClung M**. Treating Paget's disease of bone. *The Endocrinologist* 1992;2:2-28.
4. **McClung M**, Faulkner K. Techniques of bone density measurement. *Menopausal Medicine* 1993;2:7-12.
5. **McClung MR**. Osteoporosis from the perspective of an endocrinologist. *Baylor University Medical Center Proceedings* 1996;9:47-51.
6. **McClung MR**. Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. *Bone* 1996;19:195S-198S.
7. **McClung MR**, Love McClung B. Establishing an osteoporosis center. *Menopause Management* 1997;6:22-24.
8. **McClung MR**. New developments in osteoporosis. *Comprehensive Therapy* 1997;23:798-803.
9. **McClung MR**, Goldstein SR. Potential impact of emerging therapies on osteoporosis prevention. *Am J Managed Care* 1998;4:S78-S84.

10. McClung M. Results of special studies with alendronate: Int J Clin Pract (Suppl) 1999;S101:67-72.
11. McClung MR. Bisphosphonates in osteoporosis: recent clinical experience. Exp Opin Pharmacother 2000;1:225-238.
12. Gibson S and McClung MR. Osteoporosis in the aging female patient. The Female Patient, 2000;Suppl:42-46.
13. McClung MR. The use of bone turnover markers in clinical practice: what they can and cannot do. Menopausal Medicine 2000;8:4-8.
14. McClung MR. The clinical utility of bone density testing. Menopause Management 2000;9:6-12.
15. McClung MR. Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice. Ann Med Interne (Paris) 2000;151:392-398.
16. McClung MR. Osteoporosis. In EBM Solutions Guidelines for Health Care Providers and Consumers (online database). Issue 1. Nashville, Tenn: EBM Solutions 2000.
17. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocrine Practice 2001;7:293-312.
18. Gallagher JC, Ettinger B, Gass MLS, Kagan R, McClung BL, McClung MR. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause 2002;9:84-101.
19. McClung M. Management of osteoporosis in the USA. Osteoporosis Action (International Osteoporosis Foundation) 2002;6:4.
20. McClung M. Editorial: How does raloxifene reduce fracture risk? Menopause 2002;9:306-308.

INVITED REVIEWS

1. Geusens P, McClung M. Review of risedronate in the treatment of osteoporosis. Expert Opin Pharmacother 2001;2:2011-2025
2. Osteoporosis Guidelines Module for Clineguide website 2002. Clineanswers Inc.

BOOK CHAPTERS

1. Chu EW, Gershengorn M, McClung M, Hanson TA, Brennan M, Robbins J, Weintraub B. The role of fine-needle aspiration cytology in the diagnosis of thyroid cysts and nodules. In Radiation-Associated Thyroid Carcinoma, ed., LJ DeGroot. Grune and Stratton, New York, 1977, pp 347-348.
2. McClung MR, Richert-Boe K, Peterson LL, Koler RD. Decreased human erythrocyte diphosphoglycerate mutase (DPGM) concentrations in hypothyroidism. In Thyroid Research VIII, ed. JR Stockigt, and S Nagataki. Australian Academy of Science, Canberra, 1980, pp 324-326.
3. Porter GA, Elliot WC, Bennett WM, McClung M. Further evaluation of the polyuria associated with experimental aminoglycoside nephrotoxicity. In Nephrotoxicity and Ototoxicity of Drugs, ed., JP Fillastre. University of Rouen Press, Rouen, 1982, pp 95-108.
4. McClung M. Thyroid disorders. In Textbook of Geriatric Medicine: Principles and Practice, ed. Cassell, C, and Walsh, R. Springer-Verlag, New York, 1984, pp 354-381.
5. Orwoll ES, McClung MR. Calcium and mineral metabolism. In Textbook of Geriatric Medicine: Principles and Practice, ed. Cassell, C, and Walsh, R. Springer-Verlag, New York, 1984, pp 382-409.
6. Greer MA, McClung MR. Hyperthyroidism. In Current Diagnosis, ed. RB Conn, Saunders, Philadelphia, 1984, pp 836-839.
7. Lester LB, McClung M. Hyperparathyroidism and hypoparathyroidism. In Conn's Current Therapy, ed R. Rakel, W.B. Saunders, 1994, pp 595-602.
8. McClung M. Non-Pharmacologic Management of Osteoporosis. In Osteoporosis, ed. R. Marcus. Blackwell Scientific Publications, 1994, pp 336-353.

9. Wernick R, **McClung M**. Primary and Preventive Care. In Precis V - An Update in Obstetrics and Gynecology. The American College of Obstetricians and Gynecologists, 1994, pp
10. **McClung MR**, Spencer K. Nonpharmacologic therapy for osteoporosis. In Osteoporosis: Diagnostic and Therapeutic Principles. ed. C.J. Rosen, Humana Press Inc., Totowa, NJ, 1996, pp 189-199.
11. Faulkner KG, **McClung MR**. Standardization of femoral neck T-scores from Hologic and Lunar DXA systems. In Osteoporosis 1996. ed. S.E. Papapoulos et al., Elsevier Science B.V. 1996, pp 223-226.
12. **McClung MR**, Love McClung B. Osteoporosis. In Conn's Current Therapy. ed. R. Rakel, W.B. Saunders, 1997, pp 581-587.
13. **McClung MR**. Pathophysiology of fractures. In Osteoporosis in Clinical Practice: A Practical Guide for Diagnosis and Treatment. ed. P. Geusens. Springer-Verlag 1998, pp 23-29.
14. Wernick, R, **McClung M**. Rheumatic and autoimmune disorders. In Precis – An Update in Obstetrics and Gynecology – Primary and Preventive Care. 2nd Edition, American College of Obstetrics and Gynecology, 1999, pp 179-192.
15. Kleerekoper M, Siris ES, **McClung M** (Editors). Nonpharmacologic therapy. In The Bone and Mineral Manual: A Practical Guide. Academic Press 1999, pp109-111.
16. **McClung M**, Arce J-C. Total hip bone mineral density changes with several doses of 17 β -estradiol and continuous combined 17 β -estradiol and norethindrone acetate. In Proceedings of the 9th International Menopause Society World Congress on the Menopause. ed. T. Aso, T. Yanahara, Y. Taketani, T. Suda, H. Tanaka, S. Maehara. Moduzzi Editore 1999, pp 105-108.
17. **McClung M**. Assessing bone mass by x-ray absorptiometry: the WHO definition of osteoporosis. In Management of Fractures in Severely Osteoporotic Bone – Orthopedic and Pharmacologic Strategies. ed. K. Obrant. Springer-Verlag, London 2000, pp 33-43.
18. **McClung M**. Osteoporosis. ed. R. Edlich. In Advances in Medicine, ABI Professional Publications, Arlington, VA. 2000, pp 415-424.
19. McClung B, **McClung M**. Pharmacologic therapy for the treatment and prevention of osteoporosis. In Nursing Clinics of North America. W.B. Saunders Company, Bellmawr. NJ. 2000;36:433-440.

Books:

1. Kleerekoper M, Siris ES, **McClung M** (Editors). The Bone and Mineral Manual: A Practical Guide. Academic Press 1999.

CD-ROM PRESENTATIONS

1. **McClung, M**. Osteoporosis: A lifetime program for optimizing skeletal strength. Medical Economics Co. 1999.

ABSTRACTS SINCE 1999

1. Schneider DL, Greenspan SL, **McClung MR**, DeLucca P, Bonin R, Smith ME, Gormley GJ, Melton ME. Alendronate for treatment of osteoporosis in elderly female long term care facility residents: Effect on biochemical markers of bone turnover. Program, 81st Annual Meeting, Endocrine Society, 1999;443.
2. Watts N, Eastell R, **McClung M**, Fogelman I, Pack S, Ethgen D, Reginster J-Y. Risedronate in treatment of postmenopausal osteoporosis: Review of worldwide clinical efficacy results. Program, 81st Annual Meeting, Endocrine Society, 1999;55.
3. Eastell R, Watts N, **McClung M**, Fogelman I, Hooper M, Ernst T, Ethgen D, Reginster J-Y. Integrated safety analyses of risedronate in postmenopausal women. Program, 81st Annual Meeting, Endocrine Society, 1999;443.

4. **McClung M**, Balske A, Daley M, Ravn P, Bidstrup M, Wasnich R, Davis, J, Coupland C, Chilvers C, Kaur A, Cizza G. Long-term prevention of postmenopausal bone loss with alendronate effects of continuous treatment and after withdrawal. Program, 81st Annual Meeting, Endocrine Society, 1999;54-55.
5. Gallagher JC, Freeman R, Baylink DJ, Bolognese MA, Bonnick SL, Emkey RD, Greenwald MW, Layton MW, **McClung MR**. Tibolone prevents postmenopausal bone loss and is well-tolerated: Phase III trial results. *J Bone Miner Res* 1999;14(Suppl 1):S158.
6. El-Hajj Fuleihan G, Stock JL, Saifi G, **McClung MR**. Bone mineral density reporting in the US: A national random survey. *J Bone Miner Res* 1999;14(Suppl 1):S253.
7. Greenspan SL, Schneider DL, **McClung MR**, Miller PD, Schnitzer TJ, Bonin R, DeLucca P, Smith ME, Gormley GJ, Melton ME. Alendronate for treatment of osteoporosis in elderly female long-term care facility residents. *J Bone Miner Res* 1999;14(Suppl 1):S279.
8. Rosen, CJ, Bonnick SL, Miller PD, **McClung M**, Wasnich RD, Weiss SR, Woodson GC, Schnitzer TJ, Lenihan P, Ross RP. Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal calcitonin. *J Bone Miner Res* 1999;14(Suppl 1):S399.
9. Wasnich R, Davis J, **McClung M**, Balske A, Coupland C, Sahota O, Ravn P, Bidstrup M, Mantz AM, Daley M. The safety and tolerability profile of alendronate and estrogen/progestin in the prevention of postmenopausal osteoporosis. EPIC Study: Four-year results. *J Bone Miner Res* 1999;14(Suppl 1):S530.
10. Hosking D, Chilvers C, **McClung M**, Balske A, Ravn P, Bidstrup M, Wasnich R, Davis J, Mantz AM, Daley M. Effects of baseline bone mineral density on response to treatment with alendronate for four years. *J Bone Miner Res* 1999;14(Suppl 1):S530.
11. **McClung M**, Eastell R, Watts N, Fogelman I, Hooper M, Ernst T, Bettica P, Reginster J-Y. Risedronate is well tolerated in women with postmenopausal osteoporosis. *J Bone Miner Res* 1999;14(Suppl 1):S538.
12. **McClung M**, Cohen L, Weiss S, Nanavati N, Arce J-C. Total hip bone mineral density changes with several doses of 17 β -estradiol and continuous-combined 17 β -estradiol and norethindrone acetate. 9th International Menopause Society World Congress on the Menopause. Climacteric 1999;2(Suppl 1):122.
13. Schnitzer TJ, Rosen CJ, Bonnick SL, Miller PD, **McClung MR**, Wasnich RD, Weiss SR, Woodson GC, Lenihan JP, Ross RP, Wang I, Smith ME, Gormley GJ, Melton ME. Treatment of osteoporosis in postmenopausal women: alendronate vs intranasal calcitonin. *Arthritis Rheum* 1999;9(Suppl):S177.
14. Miller P, Roux C, **McClung M**, Adami S, Eastell R, Pack S, Ethgen D, Reginster J-Y. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. *Arthritis Rheum* 1999;9(Suppl):S287.
15. Daley M, Chilvers C, **McClung M**, Balske A, Ravn P, Bidstrup M, Wasnich R, Davis J, Mantz AM, Kaur A, Maragoto A, Hosking D, Cizza G. Baseline bone mineral density and response to alendronate: EPIC four year data. *Arthritis Rheum* 1999;9(Suppl):S288.
16. Schnitzer TJ, Rosen CJ, Bonnick SL, Miller PD, **McClung MR**, Wasnich RD, Weiss SR, Woodson GC, Lenihan JP, Ross RP, Wang L, Smith ME, Gormley GJ, Melton ME. Effect on biochemical markers of bone turnover: alendronate vs intranasal calcitonin. *Arthritis Rheum* 1999;9(Suppl):S291.
17. Schnitzer TJ, Greenspan SL, Schneider DL, **McClung MR**, Miller PD, Bonin R, DeLucca P, Smith ME, Gormley GJ, Melton ME. Alendronate for treatment of osteoporosis in elderly female long-term care facility residents. *Arthritis Rheum* 1999;9(Suppl):S291.
18. Kendler DL, Genant H, **McClung M**, Rosen C, Watts N. Multisite bone ultrasound measurements on a North American reference population. *Arthritis Rheum* 1999;9(Suppl):S355.
19. Bone H III, Adami S, Recker R, Felsenberg D, Crepaldi G, Pinchera A, **McClung M**, Orloff J, Santora A II, Kaur A, Yates J for the Alendronate Once-Weekly Study Group. 6th International Symposium on Clinical Disorders of Bone and Mineral Metabolism 1999:55.
20. Geusens P, Adami S, Bensen W, **McClung M**, Meunier P, Miller P, Reginster J-Y, Zipple H. Risedronate reduces risk of hip fracture in elderly women with osteoporosis. *Calcif Tiss Int* 2000;66:(Suppl 1),S67.
21. **McClung M**, Schnitzer T, Emkey R, Smith I, Foldes J, Reid I, Orloff J, Santora A, Kaur A, Freedholm D. Once-Weekly alendronate: Upper GI Safety profile. American Association of Clinical Endocrinologists Annual Meeting Program 2000:199.

22. Licata A, Harris S, Fogelman I, Johnston CC, **McClung M**, Manhart M. Risedronate-treated patients similar to placebo patients in incidence of gastrointestinal side effects and endoscopic findings. American Association of Clinical Endocrinologists Annual Meeting Program 2000:210.
23. Bone H, Adami S, **McClung M**, Felsenberg D, Orloff J, Santora A, Kaur A, Yates J. Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily. American Association of Clinical Endocrinologists Annual Meeting Program 2000:227.
24. **McClung M**. Who should we be treating? World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S46.
25. **McClung M**, Ross PD, Wasnich RD, Christiansen C, Hosking D, Thompson D, Daley M, Yates J. Most untreated women lose bone density after menopause. World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S77.
26. **McClung M**, Ross, PD, Wasnich RD, Christiansen C, Hosking D, Thompson D, Daley M, Yates J. BMD changes after 1 year predict BMD changes after 4 years. World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S111.
27. **McClung M**, Ross PD, Christiansen C, Hosking D, Thompson D, Yates J. Consistency and changes in T-score categories over 4 years among early postmenopausal women. World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S141.
28. **McClung MR**, Thompson DE. The clinical utility of NNT to reduce fractures. World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S190.
29. **McClung M**, Eastell R, Bensen W, Benhamou L, Chesnut C, Adami S, DiGennaro J, Axelrod D, Reginster J-Y. Risedronate reduces hip fracture risk in elderly women with osteoporosis. World Congress on Osteoporosis 2000, Osteoporos Int 2000;11:S207.
30. Seeman E, **McClung M**, Zippel H, Bensen W, Cooper C, Benhamou C, DiGennaro J, Zorich N, Reginster J. Rapid and sustained effect of risedronate in reducing hip fracture risk in elderly women with osteoporosis. J Bone Miner Res 2000;15 (Suppl 1):S149.
31. Rosen CJ, Schnitzer TJ, Weiss SR, **McClung M**, Wang L, Vanaman LK, Smith ME, Gormley GJ, Melton ME, Palmisano J. Alendronate vs. intranasal calcitonin: 2-year results. J Bone Miner Res 2000;15 (Suppl 1):S307.
32. Rosen CJ, Schnitzer TJ, Bonnick S, Miller PD, McClung M, Wasnich RD, Weiss SR, Woodson GC, Lenihan JP, Wang L, Ross PD, Vanaman LK, Smith ME, Yates J, Melton ME, Palmisano J. Alendronate vs. intranasal calcitonin: 2-year study. International Society for Clinical Densitometry 7th Annual Scientific Meeting, 2001:20.
33. Rosen CJ, Schnitzer TJ, **McClung M**, Miller PD, Wang L, Vanaman LK, Yates J, Melton, ME, Palmisano J. Alendronate vs. calcitonin: 2-year treatment of osteoporosis in postmenopausal women. Bone 2001;28 (Suppl):S226.
34. Cooper C, Reginster J-Y, **McClung M**, Zorich NL, Li Z. Rapid and sustained hip fracture risk reduction with risedronate in elderly women with osteoporosis. Bone, 2001; 28 (Suppl):S223.
35. Eastell R, **McClung M**, Reginster J-Y, Bensen W, Seeman E, Cline G, Law L, Chines A. Efficacy of risedronate in decreasing the incidence of femoral neck and intertrochanteric fractures in older women with osteoporosis. J Bone Miner Res 2001;16(Supp 1):S219.
36. Bensen W, Eastell R, Reginster J, **McClung M**. The effect of risedronate on hip fracture risk in elderly women with osteoporosis. J Rheumatology 2001;28(Supp 63):24.
37. **McClung M**, Wasnich R, Omizo M, Christiansen C, Ravn P, Hosking D, Wu M, A Kaur, Mantz AM, Snodgrass S, Santora A. Resolution of effect following alendronate: Six-year results from the Early Postmenopausal Interventional Cohort (EPIC) Study. J Bone Miner Res 2002;17(Suppl 1)S134.
38. **McClung M**, Wasnich RD, Recker R, Cauley JA, Ensrud K, Burdeska A, Mahoney P, Hughes C, Chesnut C. Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis. J Bone Miner Res 2002;17(Suppl 1):S157.
39. Mossman EA, Grinnell NC, Cole L, Osborn KL, **McClung MR**. Quantitative ultrasound of the heel does not predict bone density at the femoral neck more accurately than simple clinical indices in postmenopausal Caucasian women. J Bone Miner Res 2002;17(Suppl 1):S422.

40. McClung MR, Schimmer RC, Mahoney P, Christiansen C. The efficacy of 12-month oral ibandronate treatment in postmenopausal osteoporosis when taken 30 min versus 60 min before breakfast. *J Bone Miner Res* 2002;17(Suppl 1):S473.

CME PRESENTATIONS AND ACCREDITED ACTIVITIES – 2001

Osteoporosis: Today's Strategies. American Association of Clinical Endocrinologists, San Antonio, TX

Osteoporosis: Who Should We Be Treating? Baylor College of Medicine, Houston, TX

Osteoporosis: Diagnosis and Evaluation. Langley Seminar, Legacy Emanuel Hospital, Portland, OR

Guidelines for Osteoporosis Management. Practical Advances in Internal Medicine, Providence Portland Medical Center, Portland, OR

Bisphosphonate Therapy for Osteoporosis. International Society for Clinical Densitometry, Dallas, TX

Hypercalcemia. Practical Advances in Internal Medicine, Providence Portland Medical Center, Portland, OR

Common Disorders of Bone and Mineral Metabolism. Internal Medicine Board Review Course, Providence Portland Medical Center, Portland, OR

Hip Fractures in Osteoporosis: New Insights. The Endocrine Society Annual Meeting, Denver, CO

Evaluation of Secondary Causes of Osteoporosis. The Endocrine Society Annual Meeting, Denver, CO

Osteoporosis: Hard Cases of Soft Bones. American Association of Clinical Endocrinologists, San Antonio, TX.

Therapeutic Options for Osteoporosis. Joslin Diabetes Center Continuing Medical Education, Philadelphia, PA, St. Petersburg, FL; Dallas, TX; Chicago, IL; New York

Bisphosphonate Therapy for Osteoporosis: Past, Present and Future. Santa Fe Bone Symposium, Santa Fe, New Mexico.

Controversies in Bone Density Testing. Santa Fe Bone Symposium, Santa Fe, New Mexico

Osteoporosis Research. Medical Grand Rounds, Providence Portland Medical Center, Portland, OR

Osteoporosis: Current Strategies. Medical Staff Grand Rounds, Southwest Washington Medical Center, Vancouver, WA.

Endocrine Emergencies. Medical Grand Rounds, Providence Medical Center, Portland, OR

Current Strategies for Osteoporosis Management. Medical Grand Rounds, Mercy San Juan Hospital, Sacramento, CA.

Who to treat? Current Guidelines for Osteoporosis Management. New Perspectives in Osteoporosis and Diabetes. Providence Portland Medical Center, Portland, OR

The Clinical Utility of Bone Density Testing. New Perspectives in Osteoporosis and Diabetes. Providence Portland Medical Center, Portland, OR

An Appropriate Approach to Osteopenia. Endocrine Days Educational Institute, Port Ludlow, WA

Osteoporosis: Today's Strategies. American Association of Clinical Endocrinologists, California State Chapter Annual Meeting and Symposium. Anaheim, CA.

Strategies to Reduce Fracture Risk. Medical Grand Rounds, MidMichigan Medical Center, Detroit, MI

Osteoporosis. Emerging Issues in Arthritis, Asthma and Osteoporosis Conference. Michigan Public Health Institute, Novi, MI

Bone Mineral Density Testing in Children and Adults (Workshop). Emerging Issues in Arthritis, Asthma and Osteoporosis Conference, Michigan Public Health Institute, Novi, MI

Osteoporosis: Today's Strategies. Medical Grand Rounds, Blanchard Valley Regional Health Center, Findlay, OH

Bone Density Testing and Risk Assessment of Osteoporosis. 2nd Annual Osteoporosis and Metabolic Bone Disease Symposium. Northwestern University, Chicago, IL

Bone Densitometry in Clinical Practice. North American Menopause Society, New Orleans, LA

The Risk of Hip Fracture in Elderly Women. Medical Grand Rounds, St. Josephs Hospital, Hamilton, Ontario, Canada

Anabolic Therapy for Osteoporosis. Medical Grand Rounds, Toronto General Hospital, Toronto, Ontario, Canada

Hip Fracture Protection. Colorado Annual Metabolic Bone Conference, Denver, CO

Approach to the Management of Osteoporosis. Western Canadian Endocrine Society, Calgary, Canada

OTHER NATIONAL/INTERNATIONAL PRESENTATIONS - 2001

Osteoporosis Today. Serve on the Editorial Board

Bisphosphonate Therapy for Osteoporosis. Association of Medical Management of Osteoporosis in Mexico. Acapulco, Mexico.

Clinical Use of Densitometry. Association of Medical Management of Osteoporosis in Mexico. Acapulco, Mexico.

Osteoporosis: Causes and Consequences. Magisterial Tribunal on Menopause. Buenos Aires, Argentina

Osteoporosis: Causes and Consequences. Magisterial Tribunal on Menopause. Buenos Aires, Argentina

Risedronate in the treatment of osteoporosis: Who should you be treating?. International Bone and Mineral Society/European Calcified Tissue Society Joint Meeting, Madrid, Spain.

Bone Densitometry Today. Brazil Bone Density Society, Porto Alegre, Brazil.

Bisphosphonates. Brazil Bone Density Society, Porto Alegre, Brazil.

Pharmacological Strategies for Hip Fracture Prevention and Reduction. 17th Congress of the International Association of Gerontology, Vancouver, BC, Canada.

Therapeutic Interventions: How Effective are They in the Elderly? Western Osteoporosis Alliance Meeting, Vancouver, BC, Canada

Risedronate: The Latest Evidence in Osteoporotic Fracture Reduction. VIII Conference of the Spanish Bone and Mineral Society, Menorca, Spain.

CME PRESENTATIONS AND ACCREDITED ACTIVITIES – 2002

Osteoporosis: Who Should be Treated? Medical Grand Rounds, University of Southern Alabama, Mobile, AL

What's New in Antiresorptive Therapy. International Society for Clinical Densitometry Annual Meeting, Atlanta, GA

The Role of Risk Factors for Hip Fractures. National Osteoporosis Foundation CME Symposium, Honolulu, HI.

Osteoporosis in Men and Steroid-Treated Patients. Case Discussion. National Osteoporosis Foundation Annual Meeting, Honolulu, HI.

Osteoporosis: Bisphosphonate and Calcitonin Therapy. Osteoporosis Symposium, Milwaukee, WI.

Workshop on Osteoporosis. Practical Advances in Internal Medicine, Providence Portland Medical Center, Portland, OR

Sub-Clinical Thyroid Disease. Practical Advances in Internal Medicine, Providence Portland Medical Center, Portland, OR

In Addition to Bisphosphonates, Other Prevention Strategies. American College of Obstetrics and Gynecology, Oregon Chapter, Bend, OR.

What's New in Antiresorptive Therapy? University of Cincinnati Osteoporosis Program. Cincinnati, OH.

The evolving role of bone densitometry. Michigan Consortium on Osteoporosis. Troy, MI.

Bone Densitometry: Quality Assurance in Clinical Practice. Michigan Consortium on Osteoporosis, Troy, MI.

Osteoporosis: Evaluation and Management. Medical Grand Rounds, Providence Holy Cross Hospital, Mission Hills, CA

What's New in Antiresorptive Therapy. Bones & Basal: Insights for Endos Educational Forum. Fort Lauderdale, FL, Half Moon Bay, CA.

Determinants of Fracture Risk: Bone Quantity vs. Bone Quality. Bone & Basal: Insights for Endos Educational Forum. Fort Lauderdale, FL; Half Moon Bay, CA.

Current Practice/Future Trends. Rheums with a View – Educational Forum Series. New Orleans, LA; Palm Springs, CA; Bonita Springs, FL; Quebec City, Canada, Victoria, BC. Canada.

Combination Treatment of Osteoporosis. Meet the Professor Symposium. The Endocrine Society 2002 Annual Meeting, San Francisco, CA.

Clinical Challenges in Osteoporosis: The Expert's Take. Kaiser Permanente CME Program: Physical Medicine and Rehabilitation Symposium, Los Angeles, CA.

Osteoporosis Update. Oregon Nurses Association – Nurse Practitioners of Oregon Annual Conference, Portland, OR.

Current Trends in the Management of Osteoporosis. Stanford University Medical School, Palo Alto, CA.

Preventing hip fractures in elderly women: implications of clinical risk factors. Symposium entitled "Laying the Foundation for Rapid Fracture Protection in the Treatment of Osteoporosis" at the American Society of Bone and Mineral Research Annual Meeting, San Antonio, TX.

What's new in anti-remodeling therapy? The Los Angeles Bone Symposium, Huntington Memorial Hospital, Pasadena, CA.

Screening and selecting patients for treatment. North American Menopause Society Annual Meeting, Chicago, IL

Therapy of osteoporosis: antiresorptive, anabolic or both? The Endocrine Society – Endocrine Update, Portland, OR

Using densitometry to assess the success of osteoporosis therapy. Workshop. The Endocrine Society – Endocrine Update, Portland, OR

Today's Strategies for Hip Fracture Prevention. Live CME Teleconference Series sponsored by the University of Wisconsin Medical School and Enable Healthcare Communications, Inc. August-December 2002.

OTHER NATIONAL/INTERNATIONAL PRESENTATIONS - 2002

BMD-Fracture Relationship: What is the Evidence? An Insight from Geographic Variations in Bone Mineral Density and Fracture Epidemiology. Middle East Densitometry Workshop and Consensus Conference. Beirut, Lebanon.

Intervention to Prevent/Treat Osteoporosis: Review of Current Guidelines. Middle East Densitometry Workshop and Consensus Conference, Beirut, Lebanon.

Practical Management of Osteoporosis: North American Perspective. International Osteoporosis Foundation World Congress on Osteoporosis, Lisbon, Portugal.

Cost-effective diagnostic strategies for osteoporosis. XIII Pan American Congress of Rheumatology, Aruba.

Can we afford to prevent osteoporosis? XIII Pan American Congress of Rheumatology, Aruba.

Strategies for hip fracture prevention. X Congreso de Osteología y Metabolismo Mineral. Santiago, Chile.

Bone density Testing: Pearls and Problems. South African Menopause Society, Durban, South Africa.

Fracture Prevention: The Yardstick of Success. South African Menopause Society, Durban, South Africa.

APPEARS THIS WAY
ON ORIGINAL